88 FR 7 pgs. 1599-1600 - Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal; Correction
Type: NOTICEVolume: 88Number: 7Pages: 1599 - 1600
Pages: 1599, 1600Docket number: [Docket No. FDA-2018-N-3091]
FR document: [FR Doc. 2023-00390 Filed 1-10-23; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-3091]
Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal; Correction
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice; correction.
SUMMARY:
[top] The Food and Drug Administration is correcting a notice entitled "Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal" that appeared in the Federal Register of December 13, 2022. The document announced the renewal of the
FOR FURTHER INFORMATION CONTACT:
Lisa Granger, Office of Policy, Planning, Legislation and International Affairs, Food and Drug Administration, 301-796-9115, Lisa.Granger@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
In the Federal Register of Tuesday, December 13, 2022 (87 FR 76197), in FR Doc. 2022-27014, on page 76197 the following correction is made:
1. On page 76197, in the first column of the header of the document, "Docket No. FDA-2022-N-3091" is corrected to read "Docket No. FDA-2018-N-3091".
Dated: January 3, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-00390 Filed 1-10-23; 8:45 am]
BILLING CODE 4164-01-P